Addex Therapeutics Ltd (ADXN)
| Market Cap | 3.56M -62.4% |
| Revenue (ttm) | 102,808 -50.3% |
| Net Income | -8.50M |
| EPS | -0.07 |
| Shares Out | 127.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,511 |
| Open | 3.090 |
| Previous Close | 3.180 |
| Day's Range | 3.090 - 3.249 |
| 52-Week Range | 2.560 - 11.970 |
| Beta | 1.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 28, 2026 |
About ADXN
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson’s disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, ad... [Read more]
News
Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial
(RTTNews) - Addex Therapeutics (ADXN) announced that its spin-out company Neurosterix has completed Phase 1 clinical studies of NTX-253, an investigational positive allosteric modulator (PAM) of the m...
Addex Therapeutics spin-out company completes NTX-253 clinical studies
Addex Therapeutics (ADXN) announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advan...
Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a p...
Addex's Rocher Returns As Head Of Pharmaceutical Development; Kalinichev Departs For Neurosterix
(RTTNews) - Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, on Friday announced the appointment of Jean-Phillippe Rocher as the Head of Pharmaceutical Development, and a me...
Addex Therapeutics Announces Executive Management Changes
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October ...
Addex Therapeutics (ADXN): Cash Runway and Returned GABAB Rights Set the Risk
Addex Therapeutics Ltd. (ADXN) is entering its next phase with more control over a key pipeline area, but also with... The post Addex Therapeutics (ADXN): Cash Runway and Returned GABAB Rights Set the...
Addex Therapeutics Earnings Call Transcript: Q2 2026
Raised $2.8M, extending cash runway into Q4 2027, and regained full rights to the GABAB PAM program, enabling broad development opportunities. H1 2026 net loss remained stable at CHF 3.4M, with key pipeline assets advancing and new patents filed, expiring in 2044.
Addex Therapeutics Quarterly report: Q2 2026
Addex Therapeutics has published its Q2 2026 quarterly earnings report on September 28, 2026.
Addex Therapeutics Earnings release: Q2 2026
Addex Therapeutics released its Q2 2026 earnings on September 28, 2026, summarizing the period's financial results.
Addex Therapeutics (ADXN) Reports H1 2026 Losses, Cash Decline Amidst Challenging Market Valuation
Addex Therapeutics (ADXN) Reports H1 2026 Losses, Cash Decline Amidst Challenging Market Valuation
Addex Therapeutics H1 Net Loss Widens, Operating Loss Narrows; Advances GABAB PAM Cough Program
(RTTNews) - Addex Therapeutics Ltd. (ADXN, ADXN.SW) on Monday reported a wider net loss for the first half, while operating loss narrowed from last year on lower research and development expenses.
Addex Posts Narrower Loss In Q2
(RTTNews) - Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company, released its second-quarter 2026 financial results on Monday and provided corporate updates for the quarter.
Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portf...
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small ...
Can Addex Therapeutics Maintain Its Cost-Cutting Momentum In Q2?
(RTTNews) - Addex Therapeutics (ADXN) is scheduled to report its second-quarter and first-half 2026 financial results on September 28, 2026, with investors likely to focus on the company's financial p...
Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026
Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mod...
Addex Therapeutics Secures $2.8 Mln Via ATM Sale; Cash Runway Extended To Q4 2027;Stock Up
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced that it has raised gross proceeds of $2.8 million through the sale of 0.44 million American Depositary Shar...
ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfoli...
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation
Addex Therapeutics (ADXN) Reveals Promising Preclinical Results on Sleep-Wake Regulation
Addex Research Highlights MGlu7 Modulation As A Novel Pathway In Sleep And Stress Regulation
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric mo...
Addex Therapeutics announces publication of new ADX71743 preclinical research
Addex Therapeutics (ADXN) announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator of metabotropic glutamate receptor 7, significantly m...
Addex Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw strong preclinical progress in chronic cough and brain injury recovery programs, with robust efficacy and safety data. Financials showed reduced operating loss and extended cash runway, while the Neurosterix spin-out continues to advance key neuropsychiatric assets.
Addex Therapeutics Quarterly report: Q1 2026
Addex Therapeutics has published its Q1 2026 quarterly earnings report on June 25, 2026.
Addex Therapeutics Earnings release: Q1 2026
Addex Therapeutics released its Q1 2026 earnings on June 25, 2026, summarizing the period's financial results.
Addex Therapeutics Releases Q1 2026 Financial Results
Addex Therapeutics Ltd reported a dramatically narrower loss for the first quarter of 2026, as the Swiss neurological disorder specialist posted a net loss of CHF 1. The post Addex Therapeutics Releas...